Project details
Korean cancer screening company seeks investment.
| Project region | South Korea |
|---|---|
| Industry | Biomedicine |
| Total value of the target | N/A |
| Expected target net rate of return after deducting all taxes and fees | N/A |
| Validity period of pending order | 365 |
CONTACT ADVISOR
| Project highlights | nanoscale controllable - 15 years' R&D and 20 million investment - patents registered in 12 countries |
|---|---|
| Project description |
The Korean company's core technology is nanoscale controllable surface coating technology. The company aims to reliably diagnose early human cancer through the highest sensitivity, specificity and lowest detection limit. Through 15 years of research and investment of USD 20 million, the company has completed the R&D of core technology. In vitro diagnosis ("IVD") has been applied and four cardiac lateral flow immunoassay ("LFA") (sidestream analysis) kits have been completed pilotscale experiment. The company has registered patents in 12 countries including the United States and the European Union. The company now seeks investment. |
We provide expert advisory and corporate services across Asia, guiding businesses through complex markets and regulations.
Have Any Questions?
Reach out to our local experts, we’ll respond within one business day.
Our Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us
